Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2017

Steve Soper's Biography

Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas

Prof. Steven A. Soper received his Ph.D. from the University of Kansas in 1989 followed by a Postdoctoral Fellowship at Los Alamos National Laboratory, where he worked on single-molecule detection for high speed sequencing of the human genome. In 1991, he joined the faculty at Louisiana State University (LSU) within the Department of Chemistry, where he filled the William H. Pryor Distinguished Chair of Chemistry. Prof. Soper also had a joint appointment in the Mechanical Engineering Department and Department of Biological Sciences. While at LSU, he founded the Center for BioModular Multi-Scale Systems, which has as its primary charge to develop enabling and transformative tools for making environmental and health-related measurements at unprecedented speeds with full process automation directly in the field. Some of these tools include monitoring air and food/water supplies for biopathogens, determining bacterial/viral infections of unknown strains in patients, evaluating brain damage/injury, sampling blood for rare cells, such as tumor cells, and their molecular analysis and sequencing genomes in near real time. These tools consist of microfluidic and nanofluidic devices make in polymers via micro- or nanoreplication.

Prof. Soper is currently Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine at the University of Kansas. Prof. Soper also holds a joint appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. Prof. Soper is currently the Editor of the Americas for the Analyst and on the Editorial Board for Journal of Fluorescence and Journal of Micro- and Nanosystems. Prof. Soper is currently serving as a permanent Member of the Nano study panel with the National Institutes of Health. As a result of his efforts, Prof. Soper has secured extramural funding totaling $45M and has published over 295 manuscripts (h index = 44) and is the author of ten patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of rare cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer of Louisiana in 2001. Finally, Prof. Soper has granted 40 PhDs and 5 MS students under his direction.

Steve Soper Image

New Tools for Liquid Biopsies to Enable Precision Medicine

Thursday, 5 October 2017 at 10:00

Add to Calendar ▼2017-10-05 10:00:002017-10-05 11:00:00Europe/LondonNew Tools for Liquid Biopsies to Enable Precision MedicineLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island,

Liquid biopsies are generating great interest within the medical community due to the simplicity for securing important biomarkers to manage complex diseases, such as many of the cancer-related diseases. Liquid biopsy markers can facilitate the realization of Precision Medicine in terms of assisting in the discovery of new patient-specific therapies and stratifying patients to match them to appropriate therapies. We are developing a suite of novel microfluidic devices that can process whole blood directly and designed to efficiently search for a variety of disease-associated liquid biopsy markers from divergent subpopulations comprising the tumor microenvironment. The microfluidic devices can isolate the target with recovery >90% and sufficient purity (>80%) to enable downstream molecular analysis. In this presentation, I will discuss the development of a fluidic system for monitoring minimum residual disease (MRD) in acute myeloid leukemia (AML) patients following allosteric stem cell transplantation to detect signs of relapse without requiring a bone marrow biopsy. Specifically, the peripheral blood of patients were tracked longitudinally for signs of relapse using circulating leukemia cells with relapse detected nearly 2 months prior to the standard of care, which required a bone marrow aspirate and multi-parameter flow cytometry. In addition, the staging of patients with multiple myeloma will be discussed via affinity selection of circulating plasma cells using peripheral blood samples with FISH carried out on the circulating plasma cells.

Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island,